Dry Macular Degeneration: Stages and Management
Understanding Dry Macular Degeneration
Dry age-related macular degeneration (AMD) is the most common form of macular degeneration, accounting for approximately 80 to 90 percent of all AMD cases. It affects the macula, the small central area of the retina responsible for sharp, detailed vision. According to the CDC Vision and Eye Health Surveillance System, approximately 18.34 million Americans had early-stage dry AMD in 2019, while 1.49 million had progressed to the late, vision-threatening stage of the disease (CDC VEHSS, 2022). While dry AMD progresses more slowly than its wet counterpart, it can still lead to significant vision changes over time.
The macula sits at the center of the retina and is densely packed with photoreceptor cells called cones. These cells are responsible for sharp central vision, allowing you to see fine detail, recognize faces, read, and drive. When the macula is damaged by dry AMD, central vision becomes blurry or distorted while peripheral (side) vision typically remains intact. At Greenwich Ophthalmology Associates, our retina specialists in the greater NY/CT region use advanced imaging and personalized monitoring plans to help patients manage this condition at every stage.
Dry AMD involves a slow thinning of macular tissue and the accumulation of drusen, whereas wet macular degeneration occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood. Wet AMD tends to progress more rapidly and can cause sudden vision loss. Because dry AMD can convert to the wet form at any stage, regular monitoring is essential for early detection of any changes.
Age is the strongest risk factor for dry AMD, with most cases diagnosed in people over 55. Other significant contributors include a family history of AMD, smoking, light skin and eye color, obesity, and cardiovascular disease. You can learn more about the full range of contributors on our page covering AMD risk factors and prevention.
Stages of Dry AMD
Dry AMD is classified into three stages based on the size and number of drusen, the presence of pigment changes, and the extent of tissue loss in the macula. In early dry AMD, medium-sized drusen (roughly the width of an average human hair) are present beneath the retina. Most people at this stage experience no noticeable vision symptoms. The condition is usually discovered during a routine dilated eye exam, which underscores the importance of regular screenings for anyone over age 50 or with known risk factors.
Intermediate dry AMD is characterized by large drusen, pigment changes in the retina, or both. Some patients begin to notice mild blurriness or difficulty seeing in low-light conditions. This is the stage at which AREDS2 nutritional supplements have been shown to reduce the risk of progressing to advanced disease by approximately 25 percent. Our retina specialists may also increase your monitoring frequency at this point to watch for any signs of conversion.
Late-stage dry AMD, known as geographic atrophy (GA), involves clearly defined areas where the retinal pigment epithelium (RPE) and photoreceptor cells have broken down. This tissue loss leads to blind spots in central vision that can gradually enlarge over months and years. While geographic atrophy is currently irreversible, the FDA has approved complement inhibitor injections that can slow the rate of atrophy expansion, and ongoing clinical research continues to improve the outlook for patients with advanced disease.
Understanding Drusen
Drusen are a hallmark feature of dry AMD and among the first signs our retina specialists look for during a comprehensive eye examination. Hard drusen are small, well-defined deposits commonly found in the aging eye, and they are usually not a cause for concern on their own. Soft drusen are larger, have less distinct edges, and tend to cluster together beneath the retina. Soft drusen carry a considerably higher risk of progression to intermediate or advanced AMD compared to isolated hard drusen.
A few scattered hard drusen are considered a normal part of aging and do not necessarily indicate macular degeneration. However, when soft drusen are numerous or large, they suggest that the underlying retinal pigment epithelium is under stress. The presence of extensive soft drusen combined with pigmentary changes significantly raises the likelihood that measurable vision loss may develop in the coming years.
Drusen are visible during a dilated eye exam and can be documented in detail using optical coherence tomography (OCT) and fundus photography. OCT provides high-resolution cross-sectional images of the retina, enabling us to measure drusen volume and track subtle changes between visits. These imaging tools are essential for accurate staging and for determining when to adjust your management plan.
How Dry AMD Progresses Over Time
Dry AMD is a slowly progressive condition, and the rate of change varies considerably from one person to the next. Many patients remain at the early stage for years or even decades without noticeable vision changes. Progression from intermediate dry AMD to geographic atrophy can take several years, though this timeline is not predictable for any individual. Patients with large, confluent soft drusen or reticular pseudodrusen may experience a faster rate of change than those with smaller, scattered deposits.
Smoking is one of the most significant modifiable risk factors and has been shown to accelerate AMD progression substantially. Genetic factors, particularly variants in complement system genes, also play an important role. Cardiovascular health, diet, body weight, and cumulative UV exposure can all influence how quickly the disease advances.
We rely on regular OCT scans, fundus autofluorescence imaging, and fundus photography to detect subtle changes before they become apparent to the patient. These studies allow us to identify thinning retinal tissue, expanding areas of atrophy, or early signs that dry AMD may be converting to the wet form. Your monitoring schedule is tailored to your specific stage, with more frequent imaging recommended for intermediate and late disease.
Frequently Asked Questions
There is no treatment that reverses the damage already caused by dry AMD, but there are proven strategies to slow its progression. For intermediate dry AMD, AREDS2 supplements reduce the risk of advancing to late-stage disease. For geographic atrophy, FDA-approved complement inhibitor injections can slow the rate of tissue loss when administered on an ongoing basis. Our retina specialists will evaluate your specific stage and discuss which options are most appropriate for you.
AREDS2 supplements contain a specific combination of vitamins C and E, lutein, zeaxanthin, zinc, and copper. They are recommended for patients diagnosed with intermediate dry AMD or those who have advanced AMD in one eye. The formula was refined from the original AREDS study by replacing beta-carotene with lutein and zeaxanthin, making it safer for current and former smokers. For more guidance on how diet and nutrition support macular health, visit our page on nutrition for macular degeneration prevention.
The recommended frequency depends on the stage of your disease. Patients with early dry AMD are typically seen once every 12 months, while those with intermediate or late dry AMD generally need exams every 4 to 6 months. Between visits, we recommend monitoring your vision at home using an Amsler grid so you can detect new distortion or blind spots as early as possible.
Quitting smoking is the single most impactful lifestyle change you can make to slow AMD progression. Eating a diet rich in dark leafy greens, colorful fruits, and omega-3 fatty acids supports macular health over the long term. Wearing UV-protective sunglasses outdoors, maintaining a healthy weight, exercising regularly, and managing blood pressure and cholesterol all contribute as well.
Yes, dry AMD can convert to wet AMD at any stage, and this shift can happen without warning. Warning signs include new distortion or waviness when looking at straight lines, a dark or empty area appearing in your central vision, or a sudden change on your Amsler grid. If you notice any of these symptoms, contact us promptly. Wet AMD is treated with anti-VEGF injections, and early intervention offers the best chance of stabilizing your vision.
Not necessarily. Many patients with early or intermediate dry AMD maintain functional vision throughout their lives, particularly when they follow recommended monitoring schedules and take appropriate supplements. Late-stage geographic atrophy does result in central vision loss, but peripheral vision is almost always preserved, allowing most patients to maintain a degree of independence. Advances in treatment continue to improve the long-term outlook for patients at every stage of the disease.
Schedule Your Retina Evaluation
If you have been diagnosed with dry macular degeneration or have a family history of AMD, proactive monitoring can make a meaningful difference in preserving your vision. Understanding the stages of dry AMD and what you can do to protect your vision is one of the most important steps you can take.
Our fellowship-trained retina specialists at Greenwich Ophthalmology Associates bring decades of combined experience and advanced diagnostic imaging to every evaluation in the greater NY/CT region. We are here to guide you through each stage of this condition with individualized care and clear communication. Scheduling a comprehensive retina evaluation is a straightforward first step toward staying ahead of dry AMD.
What our Patients say
4.8
Reviews
(3,408)